This Article Full Text Full Text (PDF) IMPORTANT FDA ADVISORY eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Green, J. R. Search for Related Content PubMed PubMed Citation Articles by Green, J. R.

Bisphosphonates: Preclinical Review

Novartis Pharma AG, Basel, Switzerland

Correspondence: Correspondence: Jonathan R. Green, Ph.D., Novartis Pharma AG, Klybeckstrasse 141, WKL-125.901, CH-4002 Basel, Switzerland. Telephone: 41-61-696-4415; Fax: 41-61-696-3849; e-mail: jonathan.green{at}pharma.novartis.com

Bisphosphonates effectively inhibit osteoclast-mediated bone resorption and are integral in the treatment of benign and malignant bone diseases. The evolution of bisphosphonates over the past 30 years has led to the development of nitrogen-containing bisphosphonates (N-BPs), which have a mechanism of action different from that of the nonnitrogen-containing bisphosphonates. Studies conducted over the past decade have elucidated the mechanism of action and pharmacologic properties of the N-BPs. N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras. Recent evidence suggests that N-BPs also induce production of a unique adenosine triphosphate analogue (Apppi) that can directly induce apoptosis. Our increased understanding of the pharmacologic effects of bisphosphonates is shedding light on the mechanisms by which they exert antitumor effects. As a result of their biochemical effects on protein prenylation, N-BPs induce caspase-dependent apoptosis, inhibit matrix metalloproteinase activity, and downregulate _vß₃ and _vß₅ integrins. In addition, zoledronic acid (Zometa^®; Novartis Pharmaceuticals Corp.; East Hanover, NJ and Basel, Switzerland) exerts synergistic antitumor activity when combined with other anticancer agents. Zoledronic acid also inhibits tumor cell adhesion to the extracellular matrix and invasion through Matrigel^TM and has antiangiogenic activity. A growing body of evidence from animal models demonstrates that zoledronic acid and other bisphosphonates can reduce skeletal tumor burden and prevent metastasis to bone. Further studies are needed to fully elucidate these biochemical mechanisms and to determine if the antitumor potential of bisphosphonates translates to the clinical setting.

Key Words. Bisphosphonates • Zoledronic acid • Bone resorption • Apoptosis • Antitumor effects • Mevalonate pathway

This article has been cited by other articles:

				P. Zwolak, J. C. Manivel, P. Jasinski, M. N. Kirstein, A. Z. Dudek, J. Fisher, and E. Y. Cheng Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines J. Bone Joint Surg. Am., January 1, 2010; 92(1): 162 - 168. [Abstract] [Full Text] [PDF]

				S. Pozzi, S. Vallet, S. Mukherjee, D. Cirstea, N. Vaghela, L. Santo, E. Rosen, H. Ikeda, Y. Okawa, T. Kiziltepe, et al. High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties Clin. Cancer Res., September 15, 2009; 15(18): 5829 - 5839. [Abstract] [Full Text] [PDF]

				P. L. Bedard, J.-J. Body, and M. J. Piccart-Gebhart Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer J. Clin. Oncol., September 1, 2009; 27(25): 4043 - 4046. [Full Text] [PDF]

				E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., August 1, 2009; 20(8): 1303 - 1317. [Abstract] [Full Text] [PDF]

				M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Onc., March 1, 2008; 19(3): 420 - 432. [Abstract] [Full Text] [PDF]

				A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Oncologist, September 1, 2007; 12(9): 1035 - 1043. [Abstract] [Full Text] [PDF]

				M. D. Mason, M. R. Sydes, J. Glaholm, R. E. Langley, R. A. Huddart, M. Sokal, M. Stott, A. C. Robinson, N. D. James, M. K. B. Parmar, et al. Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873) J Natl Cancer Inst, May 16, 2007; 99(10): 765 - 776. [Abstract] [Full Text] [PDF]

				F. Scotte, J.-M. Tourani, E. Banu, M. Peyromaure, E. Levy, S. Marsan, E. Magherini, E. Fabre-Guillevin, J.-M. Andrieu, and S. Oudard Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand J. Clin. Oncol., July 1, 2005; 23(19): 4424 - 4429. [Abstract] [Full Text] [PDF]

				P. Conte Optimizing Bisphosphonate Therapy in Oncology Oncologist, September 1, 2004; 9(suppl_4): 1 - 2. [Full Text] [PDF]